Table 1.
Demographic and clinical outcome
| Total | Outcome | |||
|---|---|---|---|---|
| Completely stone-free | Stone-free with CIRFs | Not stone-free | ||
| No. treated cases | 72 | 32 (44) | 37 (51) | 35 (49) |
| No. male (%) | 42/72 (58.3) | 20/32 (62.5) | 25/37 (67.6) | 18/35 (51.4) |
| No. left side (%) | 34/72 (47.2) | 15/32 (46.9) | 19/37 (51.4) | 16/35 (45.7) |
| No. stone location (%) | ||||
| Upper pole | 2/72 (2.8) | 2/32 (6.3) | 2/37 (5.4) | |
| Midpole | 7/72 (9.7) | 4/32 (12.5) | 4/37 (10.8) | 5/34 (14.7) |
| Lower pole | 33/72 (45.8) | 18/32 (56.3) | 21/37 (56.8) | 15/35 (42.9) |
| Renal pelvis | 29/72 (40.3) | 8/32 (25.0) | 10/37 (27.0) | 14/35 (40.0) |
| Missing | 1/72 (1.4) | 1/35 (2.9) | ||
| Measures of stone burden | ||||
| No. of stones | ||||
| 1 | 69/72 (96) | 32/32 (100) | 36/37 (97.3) | 33/35 (94.3) |
| 2 | 3/72 (4) | 1/37 (2.7) | 2/35 (5.7) | |
| Stone axis length | ||||
| Major axis length; mma | 6.9 (5.7–8.9 [3.4–20.1]) | 6.2 (5.2–8.1 [3.4–11.8]) | 6.3 (5.2–8.1 [3.4–13.8]) | 7.7 (6.0–10.8 [3.9–20.1]) |
| Vertical axis length; mma | 7.5 (5.7–10.5 [2.6–21.0]) | 6.7 (5.3–8.1 [3.7–12.7]) | 6.8 (5.0–8.6 [3.7–12.7]) | 9.0 (6.0–11.4 [2.6–21.0]) |
| Stone volume(s); mm3a | 113 (62–276 [21–1820]) | 74 (56–141 [21–350]) | 80 (58–168 [21–518]) | 199 (77–396 [8–1820]) |
| Total no. of pixelsa | 220 (139–485 [30–3224]) | 190 (131–391 [65–966]) | 200 (142–446 [65–1615]) | 238 (133–511 [30–3224]) |
| No. SWL sessions | ||||
| 1 | 60/72 (83.3) | 30/32 (93.8) | 35/37 (94.6) | 27/35 (77.1) |
| 2 | 10/72 (13.9) | 1/32 (3.1) | 1/37 (2.7) | 7/35 (20.0) |
| 3 | 1/72 (1.4) | |||
| ≥ 4 | 1/72 (1.4) | 1/32 (3.1) | 1/37 (2.7) | 1/35 (2.9) |
CIRFs, clinically insignificant residual fragments; CT KUB, computed tomography kidneys ureter bladder; SWL, shockwave lithotripsy
aValues were measured using the StoneChecker software. ‘Stone-free with CIRFs’ are patients who are completely stone-free or patients who had CIRFs after treatment. ‘Completely stone-free’ is a subset of ‘Stone-free with CIRFs’ for patients who are completely stone-free only. ‘Not stone-free’ are patients who have residual fragments after treatment which are larger than CIRFs. ‘Total’ includes the sum of patients who are ‘Stone-free with CIRFs’ and ‘Not stone-free’